SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 128.51 |
| Enterprise Value ($M) | 89.99 |
| Book Value ($M) | 76.41 |
| Book Value / Share | 1.15 |
| Price / Book | 1.68 |
| NCAV ($M) | 74.57 |
| NCAV / Share | 1.13 |
| Price / NCAV | 1.72 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.60 |
| Return on Assets (ROA) | -0.41 |
| Return on Equity (ROE) | -0.43 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.52 |
| Current Ratio | 10.98 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 82.34 |
| Assets | 84.18 |
| Liabilities | 7.77 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -50.04 |
| Net Income | -46.36 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -41.67 |
| Cash from Investing | -35.98 |
| Cash from Financing | 92.42 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Point72 Asset Management, L.P. | 5.90 | 62.71 | |
| 13G/A | Ra Capital Management, L.p. | 1.20 | -87.73 | |
| 13G/A | Biotechnology Value Fund L P | 1.30 | -90.85 | |
| 13G/A | DAFNA Capital Management LLC | 1.37 | -19.43 | |
| 13G/A | Vanguard Group Inc | 6.24 | 0.00 | |
| 13G | BlackRock, Inc. | 6.20 | 0.00 | |
| 13G | Octagon Capital Advisors LP | 6.50 | ||
| 13G/A | Fmr Llc | 4.46 | 0.00 | |
| 13G | Deep Track Capital, LP | 9.99 | ||
| 13G | Vivo Opportunity Fund Holdings, L.P. | 7.70 | ||
| 13D/A | Growth Equity Opportunities V, LLC | 9.99 | 235.79 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 195,782 | 1,248,675 | 15.68 | |
| 83,514 | 429,542 | 19.44 | |
| 101,229 | 524,590 | 19.30 | |
| 61,080 | 527,168 | 11.59 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RENB – Renovaro Inc. | REVB – Revelation Biosciences, Inc. |
| RGC – Regencell Bioscience Holdings Limited | RMTI – Rockwell Medical, Inc. |
| RNAZ – TransCode Therapeutics, Inc. |